Oncology

Latest News

December 23rd 2024

Prior authorization, PBM reform, and payment for patient navigation were topics of the most popular articles in EBO in 2024.

ICYMI: Highlights From ASCO 2024

By Pearl Steinzor

December 21st 2024

chemotherapy | Image credit: Penn Medicine

The High Cost of Shortages of Low-Cost Chemotherapy

By Interview by Mary Caffrey

December 19th 2024

Leukemia diagnosis | Image credit: Vitalii Vodolazskyi - stock.adobe.com

Real-World Treatment Sequences and Cost Analysis of cBTKis in CLL

By Pearl Steinzor

December 17th 2024

FDA approved stamp in black with a red ribbon across it | Image credit: BHM - stock.adobe.com

Cosibelimab Approved for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

By Kristi Rosa

December 16th 2024

Join this panel as they discuss treatment for metastatic NSCLC patients without driver mutations.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

December 5th 2014

Markers for Mental Health Problems in Cancer Patients Identified

December 5th 2014

Rapid Progress in Bench-to-Clinic Reported for Several Cancers

The results were presented at the recent Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, a meeting jointly sponsored by the NCI, AACR, and EORTC.

December 4th 2014

340B: A Double-Edged Sword

While ASCO is calling to update the 340B drug discount program, hospitals that serve economically diverse populations make a case for the program: "Because of 340B, we don't have to turn patients away when they can't pay."

December 4th 2014

ASH Adds to the "Choosing Wisely" List

The American Society of Hematology has added 5 more recommendations to it's Choosing Wisely list, which was published in the journal Blood,

December 4th 2014

Xalkori Shows Significant Benefit As First-Line in ALK-Positive NSCLC

The study, published in NEJM, found that PFS improved by nearly 4 months while ORR improved by nearly 30%.

December 4th 2014

Prostate Cancer Diagnostic Test Could Prevent Over or Under Treatment

By distinguishing low- and intermediate-risk patients, Oncotype DX is predicted to avoid over- and under-treatment of prostate cancer patients.

December 3rd 2014

Amgen's Blincyto Approved for B-Cell ALL

Blincyto, which was considered a promising immunotherapy with a novel mechanism of action, was approved 5 months prior to its PDUFA date.

December 3rd 2014

Gene Could Be a New Biomarker For Diagnosis of TNBC

Absence of a microRNA in TNBC resulted in the overexpression of RASAL2 in those tumors. Patients overexpressing RASAL2 had poorer survival, research showed.

December 3rd 2014

Most People Dismiss Early Signs of Cancer: PLOS ONE Study

People could be putting their lives at risk by dismissing potential warning signs of cancer as less serious symptoms, according to a Cancer Research UK-funded study published in PLOS ONE. The survey found that nearly 97% of people with symptoms failed to act on them.

December 2nd 2014

Bisphosphonates Can Prevent Certain Cancers: PNAS Study

A study found new indications for a drug that is widely used in the treatment of osteoarthritis, based on an observation that those on the medication had a lower incidence of several cancers.

December 2nd 2014

Astra Files NDA for Iressa as First-Line in NSCLC

Iressa, an EGFR inhibitor, is widely used in the treatment of advanced, metastatic NSCLC.

December 1st 2014

Cabozantinib Fails to Meet Primary End-Point in mCRPC

Failure of the drug in the phase 3 COMET-2 study was anticipated following the reported failure of the earlier COMET-1 trial.

November 30th 2014

AJMC Stakeholder Summit Explores Challenges in Using Data to Make Decisions in Oncology

What makes a cancer therapy effective may be in the eye of the stakeholder, even though everyone involved in healthcare decisions relies on evidence-based information. Evidence-Based Oncology, a publication of The American Journal of Managed Care, this month publishes a condensed version of the discussion among payers on how to improve collection and use of collection of data to make better evidence-based decisions in oncology.

November 30th 2014

Genes Could Predict

The NIH-funded study, published in the New England Journal of Medicine, identified mutations that are harbored early and could be potential early-onset biomarkers for detection.

November 29th 2014

A 2-Drug Combination Successfully Thwarts Colorectal Cancer

A study by the University of Colorado Cancer Center published in the journal PLoS ONE and concurrent phase I clinical trial is examining a new strategy: targeting both important cancer-causing pathways simultaneously.

November 28th 2014

Specialty Drugs a Rising Healthcare Cost

Surabhi Dangi-Garimella, PhD

Early this week, Novation, a healthcare services company that oversees supply chain management, called on Genentech to reverse its decision to use only specialty drug distributors instead of wholesale distributors for its widely used anticancer treatments, Avastin, Rituxan, and Herceptin.

November 28th 2014

International Variation in Drug Usage

A new RAND study explores the range of possible causes that might explain observed international variations in the usage of medicines for selected disease areas: dementia, osteoporosis, cancer, diabetes, and hepatitis C.

November 28th 2014

Dr Peter P. Yu Describes the Many Dimensions to Providing Quality Cancer Care

There are many dimensions to providing quality cancer care, but they're always tied to aligning the best outcomes with the patient's preferences, Peter P. Yu, MD, FASCO, 2014-2015 president of ASCO, said at the Patient-Centered Oncology Care meeting.

November 26th 2014

Yale Study Shows PD-L1 Expression Can Predict Response to PD-L1 Inhibitors

The trial, conducted across various tumor types, monitored PD-L1 expression in biopsy samples before and during treatment with the PD-L1 inhibitor MPDL3280A being developed by Genentech.

November 26th 2014

Pre-Op Work Can Prevent Risks Associated With Morcellation: Study Finds

Following on the heels of the FDA's advice on the risk of using morcellators for treating fibroids, researchers in France have released results of a study that delineates a method that can avoid the risk of morcellating a pre-existing uterine sarcoma.

November 26th 2014

How Medicaid Reimbursements Impact Cancer Screening Rates

Laura Joszt, MA

Physicians who receive higher reimbursements for routine office visits are more likely to perform cancer screening tests on Medicaid beneficiaries, according to a new study in Cancer.

November 25th 2014

Gene that Could Identify Tamoxifen-Resistant Breast Cancer Discovered

The study, published in PNAS, identified a gene whose expression could be used as a prognostic indicator and could direct treatment in breast cancer patients.

November 25th 2014

Restricted Specialty Drug Distribution Could Raise Cancer Drug Costs

Genentech's decision to use a handful of specialty drug distributors instead of wholesalers for the distribution of the most commonly used anticancer medications has raised concerns of availability and cost.

November 25th 2014

Study Strengthens Link Between Obesity and Prostate Cancer

The large retrospective study, conducted in 9.8 million men, identified a strong association between obesity and the development of an advanced and more aggressive form of the disease.

November 24th 2014

Amgen's Rilotumumab Fails...Again

The monoclonal antibody,a c-Met inhibitor, was being tested in advanced gastric cancer patients following it's revival 2 years back.

November 24th 2014

FDA Update on the Use of Power Morcellators

In the update, the FDA is now asking the device manufacturers to include a black box warning and contraindications, to warn both providers and patients of possible health risks with the procedure.

November 24th 2014

The Road to Extinction: Oncology Private Practice

This article in The New York Times details the reasons why private oncology practices are being forced to consolidate to stay afloat.

November 24th 2014

Northwestern Study Discovers Treatment For Pediatric Gliomas

The study, published in Nature Medicine, identified a small molecule inhibitor that increases histone methylation, compensating for the reduced methylation caused by mutation in the H3F3A gene, resulting in gliomas.

November 23rd 2014

Preclinical Model to Guide Immunotherapeutic Development

Champions Oncology will be presenting data on it's preclinical model at the ongoing EORTC-NCI-AACR Symposium in Barcelona. The model proposes to help develop individualized treatments for patients.

November 22nd 2014

MSKCC Research Provides Lead On Immuno-oncology Resistance

Scientists at the Memorial Sloan Kettering Cancer Center have identified that tumor mutation burden could help predict responders to ipilimumab treatment. The report has been published online in the New England Journal of Medicine.

...

141 142 143 144 145 146 147 148 149

...

181 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions